Da Hee Han, PharmD

Alprazolam was found to be the most commonly misused benzodiazepine.

The pooled analysis (N=804) evaluated clinical studies of sufentanil sublingual tablet (SST) at 30mcg dose equivalents over ≤72 hours for moderate-to-severe acute pain management in both postoperative and emergency room patients.

Apadaz was initially approved in February 2018 as 6.12mg/325mg immediate-release tablets for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Currently, naloxone is supplied in ampules and vials for IV, IM or SC administration, in a prefilled auto-injector, and as a nasal spray.

Brixadi utilizes FluidCrystal Injection Depot Technology; once in contact with fluids in the tissue, the solution turns into a nanostructured liquid-crystalline gel allowing for slow release of buprenorphine at a steady rate over 1 week or 1 month.

reSET-O is intended for use as an adjunct to outpatient treatment that includes transmucosal buprenorphine (medication-assisted-treatment [MAT]) and contingency management for patients aged ≥18 years who are currently under clinician supervision.

Ingesting nonsteroidal anti-inflammatory drugs (NSAID) at a higher potency level may cause nausea, vomiting, epigastric pain, diarrhea, tinnitus, headache, and even gastrointestinal bleeding; pediatric patients are also at greater risk of developing NSAID-associated renal injury.

Currently, same-day delivery is available only in Dallas, Chicago, New York City, Gainesville, Miami, Tampa, and Fort Lauderdale; this program will be expanded in 2019.

The FDA clearance was based on data from 2 studies.

reSET is a 90-day (12-week) digital therapy intended to provide cognitive behavioral therapy in patients aged ≥18 years who are currently enrolled in outpatient treatment under clinician supervision.